摘要: With the FDA insisting on more studies before it will consider approval of its new antibiotic and needing money to pay for them, Switzerland-based Basilea figures it might sell some assets to raise th ...
| With the FDA insisting on more studies before it will consider approval of its new antibiotic and needing money to pay for them, Switzerland-based Basilea figures it might sell some assets to raise the money. And the assets it has are itself and its EU tax base, Bloomberg reported. And so the Basel-based biotech is offering itself up to any U.S.-based pharma that wants to make what might be called a tit for tax deal |
我们提供专业的服务， 从产品定位、机械的生产制造，我们 实力出众，只因我们更努力
公司生产的生物反应器及各种配套设备，可替代国外同类产品的垄断，并帮助企业节省生产成本，同时提供生产过程中各种技术支持。
我们一如既往地根据用户的需求、市场环境、企业状况等进行综合分析并提供真实可靠的解决方案，迄今为止服务上千家企业。
我们将致力于优质的技术服务确保每个机械设备的安全，用更成熟的方案解决每一个问题，为企业提供一站式服务。
